Stock listing

NASDAQ:SPRY ARS Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of ARS Pharmaceuticals, Inc.

Follow ARS Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:SPRY

$2.96 USD -0.73 (-19.8%)

Close on Nov 20, 2026

Past year -56.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.86 – $3.47 USDNov 20, 2026
Volume
2.78M sharesNov 20, 2026
Market cap
$297.6M USDAt the close on Nov 20, 2026 · price × 100.5M shares outstanding
52-week range
$2.44 – $13.15 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$7.42M USDMedian day 1.58M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
ARS Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:SPRY · Home$2.96 USD-0.73 (-19.8%)2,784,259$3.28$3.465$2.855$3.69Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SPRY · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.96-0.73-19.8%$3.28$3.465$2.8552,784,259
$3.69+0.04+1.1%$3.64$3.75$3.431,695,671
$3.65+0.06+1.7%$3.52$3.785$3.521,191,124
$3.59-0.30-7.7%$3.85$4.00$3.593,284,852
$3.89+0.08+2.1%$3.86$3.995$3.791,297,321
$3.81-0.14-3.5%$3.90$4.106$3.802,288,934
$3.95+0.38+10.6%$3.57$4.13$3.573,845,251
$3.57+0.42+13.3%$3.15$3.74$3.072,904,156
$3.15+0.36+12.9%$2.81$3.17$2.733,185,284
$2.79+0.14+5.3%$2.66$2.84$2.445,672,081
$2.65-0.40-13.1%$3.05$3.095$2.602,768,593
$3.050.000.0%$3.13$3.225$2.9952,494,294
$3.050.000.0%$3.05$3.11$2.922,422,127
$3.05-0.33-9.8%$3.40$3.479$2.912,121,083
$3.38-0.28-7.7%$3.62$3.79$3.341,754,250
$3.66+0.01+0.3%$3.70$3.90$3.6252,044,359
$3.65-0.08-2.1%$3.66$3.73$3.5252,534,720
$3.73-0.19-4.8%$3.92$3.945$3.641,643,261
$3.92-0.11-2.7%$4.03$4.09$3.901,433,829
$4.03-0.29-6.7%$4.28$4.28$3.9951,522,100
$4.32+0.14+3.3%$4.13$4.355$4.131,786,600
$4.18-0.11-2.6%$4.32$4.42$4.1651,010,600
$4.29+0.06+1.4%$4.25$4.44$4.2251,542,700
$4.23+0.21+5.2%$4.07$4.32$4.001,509,000
$4.02-0.05-1.2%$4.08$4.08$3.812,332,000
$4.07+0.14+3.6%$3.99$4.095$3.942,220,100
$3.93-0.12-3.0%$4.01$4.095$3.8851,728,800
$4.05-0.13-3.1%$4.18$4.18$3.9951,546,800
$4.18-0.05-1.2%$4.20$4.27$4.061,274,300
$4.23-0.33-7.2%$4.53$4.555$4.201,258,400
$4.56+0.20+4.6%$4.35$4.635$4.211,584,900
$4.36+0.065+1.5%$4.24$4.402$4.2051,297,800
$4.295+0.005+0.1%$4.31$4.31$4.081,219,200
$4.29+0.22+5.4%$4.13$4.395$4.031,621,100
$4.07-0.05-1.2%$4.16$4.27$3.9851,828,500
$4.12-0.19-4.4%$4.35$4.395$4.111,971,600
$4.31-0.09-2.0%$4.43$4.45$4.241,297,400
$4.40+0.27+6.5%$4.11$4.435$4.011,274,700
$4.13+0.05+1.2%$4.06$4.19$4.00949,800
$4.08-0.07-1.7%$4.18$4.18$4.021,035,000
$4.15-0.03-0.7%$4.21$4.24$4.071,052,600
$4.18-0.30-6.7%$4.49$4.49$4.111,370,300
$4.48+0.13+3.0%$4.40$4.57$4.361,268,000
$4.35+0.24+5.8%$4.16$4.385$4.071,197,900
$4.11-0.04-1.0%$4.10$4.20$4.101,885,800
$4.15-0.015-0.4%$4.26$4.30$4.121,870,600
$4.165-0.085-2.0%$4.25$4.365$4.1251,451,900
$4.25-0.25-5.6%$4.50$4.50$4.222,776,000
$4.50-0.26-5.5%$4.80$4.90$4.4552,165,300
$4.76-0.30-5.9%$5.13$5.19$4.732,570,800
$5.06-0.17-3.3%$5.20$5.22$5.021,091,300
$5.23-0.16-3.0%$5.35$5.38$5.215874,500
$5.39-0.23-4.1%$5.515$5.535$5.3051,086,500
$5.62-0.05-0.9%$5.60$5.70$5.54849,500
$5.67-0.15-2.6%$5.86$5.90$5.6051,088,200
$5.82+0.05+0.9%$5.86$6.00$5.7451,196,700
$5.77-0.23-3.8%$6.08$6.08$5.741,358,000
$6.00+0.11+1.9%$5.87$6.09$5.6151,984,600
$5.89-0.14-2.3%$6.00$6.03$5.8551,190,300
$6.030.000.0%$6.03$6.12$5.891,190,800
$6.03+0.31+5.4%$5.70$6.09$5.671,162,100
$5.72+0.37+6.9%$5.40$5.76$5.391,715,834
$5.35-0.155-2.8%$5.40$5.46$5.201,936,733
$5.5050.000.0%$5.52$5.60$5.4651,267,900
$5.505-0.875-13.7%$6.30$6.35$5.502,114,100
Ticker
NASDAQ:SPRY
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All ARS Pharmaceuticals, Inc. news

ARS Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
23 in the last 12 months · 94 in all · newest Nov 5, 2026 · oldest 2023
Calls
9 calls with a replay · 9 with a transcript · latest Nov 5, 2026
Decks
20 decks · latest May 15, 2026

Where ARS Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:SPRY · Home listing · This pageNASDAQUnited StatesUSD
BOATS:SPRYBOATSUnited StatesUSD

Valuation

EV/sales 2.3× against a median of 2.6×: 6th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$281.0M USD
P/E
Loss
EV/sales
2.3×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
Not reported
Operating margin
−161.5%
Net margin
−163.6%
Debt to equity
Negative equity
Beta vs S&P 500
2.09

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
ARS Pharmaceuticals, Inc. · NASDAQ:SPRYUS$297.6MUS$281.0Mn/a2.3×n/an/a−163.6%n/a2.09
Standard Chemical & Pharmaceutical Co. Ltd. · TWSE:1720US$316.1MUS$277.1M10.1×1.3×4.8×1.7×14.5%0.2×n/a
Enwei Pharmaceutical Co., Ltd. Class A · SZSE:301331US$309.7MUS$266.0M54.6×2.1×n/a2.0×4.6%0.2×n/a
Ind-Swift Laboratories Ltd. · NSE:INDSWFTLABUS$302.3MUS$263.1M33.5×3.2×23.7×1.9×11.1%0.0×n/a
Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A · SSE:605199US$287.7MUS$344.3Mn/a3.8×n/a7.2×−68.9%1.5×n/a
Chengdu Huasun Technology Group Inc., Ltd. Class A · SZSE:000790US$285.5MUS$277.5Mn/a4.4×n/a2.7×−57.2%0.1×n/a
Tiansheng Pharmaceutical Group Co. Ltd. Class A · SZSE:002872US$279.7MUS$239.5Mn/a3.1×n/a1.0×−10.6%0.0×n/a
Bukwang Pharmaceutical Co., Ltd. · KRX:003000US$278.6MUS$153.0M42.7×1.0×n/a1.1×4.1%0.0×n/a
Ildong Pharmaceutical Co., Ltd. · KRX:249420US$277.9MUS$233.1M8.6×0.5×6.3×1.4×7.5%0.0×n/a
Deva Holding A.S. · BIST:DEVAUS$276.9MUS$245.1Mn/a0.6×4.4×0.4×−3.9%0.1×n/a
Honz Pharmaceutical Co., Ltd. Class A · SZSE:300086US$276.0MUS$298.2Mn/a5.9×n/a2.2×−62.4%0.2×n/a
Median of the othersUS$282.6MUS$264.5M33.5×2.6×5.6×1.8×0.1%0.1×

Forecasts

3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
17.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.91 · 3 analysts
Revenue, year to Dec 2026
120.4M · 4 analysts

Team and board

Officers

OfficerRole
Donn CasalePresident, Chief Executive Officer and Director
Kathleen ScottChief Financial Officer
Brian T. DorseyChief Operating Officer
Alexander FitzpatrickChief Legal Officer
John SlebirChief Legal Officer
Daniel RelovskySenior Vice President, Marketing
Lynda HarrisVice President, Human Resources
Justin ChakmaChief Business Officer
Meg SmithChief Commercial Officer
Randall KayeChief Medical Officer

Board

DirectorRole
Pratik ShahDirector and Chair of the Board
Brenton SaundersDirector
Donn CasalePresident, Chief Executive Officer and Director
Laura ShawverDirector
Michael KellyDirector
Peter A. ThompsonDirector
Peter KolchinskyDirector
Phillip SchneiderDirector
Rajeev DadooDirector
Richard LowenthalDirector
Saqib IslamDirector

Events

Results days

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close+5.3%
Q2 2026Aug 13, 2026 · After close−7.4%
Q1 2026May 15, 2026 · Before open−6.5%
Q4 2025Mar 19, 2026−1.6%
Q3 2025Nov 10, 2025 · Before open+0.3%
Q2 2025Aug 13, 2025 · Before open−5.0%
Q1 2025May 14, 2025 · Before open−9.4%
Q4 2024Mar 19, 2025 · Before open+1.0%
Q3 2024Nov 13, 2024 · Before open−15.2%
Q2 2024Aug 6, 2024 · After close−2.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close−0.7%
Q4 2023Mar 21, 2024 · After close−3.9%
Q3 2023Nov 9, 2023 · After close+8.8%
Q2 2023Aug 10, 2023 · After close−0.3%
Q1 2023May 15, 2023 · Before open−2.9%
Q4 2022Mar 23, 2023 · After close−4.0%
Q3 2022Nov 2, 2022 · After close−2.7%
Q2 2022Aug 11, 2022 · After close−1.9%
Q1 2022May 12, 2022 · After close−2.3%
Q4 2021Mar 31, 2022 · After close−8.6%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (May 2026)Investor deck22 slidesMay 15, 2026
Q4 2025 Earnings PresentationEarnings22 slidesMar 9, 2026
Investor Presentation (November 2025)Investor deck19 slidesNov 10, 2025
Q3 2025 Earnings PresentationEarnings10 slidesNov 10, 2025
Q2 2025 Earnings PresentationEarnings18 slidesAug 13, 2025
43rd Annual J.P. Morgan Healthcare Conference 2025Conference15 slidesJan 13, 2025
Corporate Update (August 2024)Corporate update30 slidesAug 12, 2024
Investor Presentation (June 2024)Investor deck32 slidesJun 28, 2024
Investor Presentation (June 2024)Investor deck33 slidesJun 28, 2024
Investor Presentation (May 2024)Investor deck41 slidesMay 10, 2024
All 20 decks
DeckKindSlidesDate
Investor Day (March 2024)Investor day72 slidesMar 7, 2024
Investor Presentation (September 2023)Investor deck17 slidesSep 25, 2023
Investor Presentation (May 2023)Investor deck36 slidesMay 16, 2023
Investor Presentation (March 2023)Investor deck41 slidesMar 13, 2023
Q1 2023 Earnings PresentationEarnings26 slidesFeb 14, 2023
Investor Presentation (December 2022)Investor deck25 slidesDecember 2022
Q4 2022 Earnings PresentationEarnings28 slidesNov 1, 2022
Merger or Acquisition (July 2022)Merger or acquisition33 slidesJul 21, 2022
Silverback Therapeutics — Corporate Update (March 2022)Corporate update18 slidesMar 31, 2022
Silverback Therapeutics — Investor Presentation (September 2021)Investor deck35 slidesSep 16, 2021

Open Decks

IPO

Went public as Silverback Therapeutics, Inc. Priced at US$21.00 a share on Dec 3, 2020.

Price
US$21.00 a share
Shares offered
11,500,000 shares of common stock
Offering size
US$241.5 million
Underwriters' option
Up to 1,725,000 more shares
Underwriters
Goldman Sachs & Co. LLC, SVB Leerink, Stifel, H.C. Wainwright & Co. · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceOct 2, 2020
Filed publiclyNov 10, 2020
Amended twiceNewest Dec 3, 2020
Shares registered with an exchangeDec 1, 2020
Declared effective by the SECDec 3, 2020
Final prospectus, with the priceDec 4, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Dec 4, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue84.3M89.1M30.0K1.32M5.51M17.8M
Cost of revenue20.4M20.6M017.1M213.0K14.1M1.55M1.42M
Gross profit63.9M68.6M30.0K-15.8M5.29M3.77M-1.55M-1.42M
Research and development13.2M19.6M20.3M18.4M20.3M24.6M21.5M14.8M
Selling, general and administrative230.1M71.7M47.3M603.0K4.69M4.23M
Operating income-179.4M-3.08M-67.5M-35.5M-19.5M-32.9M-24.1M-18.3M
Depreciation and amortization1.37M79.0K100.0K100.0K213.0K637.0K1.55M1.42M
EBITDA-178.1M-3.00M-67.4M-35.4M-19.2M-32.3M-22.5M-16.9M
Interest expense2.60M0834.0K106.0K29.0K
Income before tax-171.4M8.29M-54.4M-34.7M-20.2M-1.06M-24.0M-17.6M
Income tax-80.0K288.0K0000
Net income-171.3M8.00M-54.4M-34.7M-20.2M-32.9M-24.0M-17.6M
Earnings per share, basic-1.740.08-0.57-0.87-0.70-11.33-0.72-0.53
Earnings per share, diluted-1.740.08-0.57-0.87-0.70-11.33

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents41.3M50.8M71.0M210.5M60.1M386.6M9.98M20.2M
Short-term investments203.7M263.2M157.4M63.9M0
Receivables25.3M8.18M01.01M1.00K384.0K
Inventory31.4M10.5M0-1.01M-6.78M-2.61M
Current assets284.9M334.3M231.7M277.7M60.7M390.7M10.5M20.8M
Property, plant and equipment2.46M1.07M574.0K329.0K72.0K1.62M
Total assets327.7M351.2M233.2M281.4M61.4M394.8M15.6M27.5M
Accounts payable5.72M9.87M759.0K1.66M1.79M2.58M3.52M775.0K
Current liabilities39.1M23.4M2.39M5.44M8.19M9.60M17.9M5.14M
Long-term debt96.4M4.93M7.46M
Total debt96.4M0274.0K481.0K9.03M10.0M15.6M7.73M
Total liabilities213.4M94.4M2.43M8.55M16.7M11.9M21.3M9.35M
Shareholders' equity114.3M256.8M230.8M272.9M-31.3M-14.1M-5.60M18.2M
Shares outstanding99.3M98.0M96.4M93.9M30.4M34.7M33.1M33.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-170.9M13.5M-59.3M-40.1M-17.6M-31.2M-18.9M-16.9M
Capital spending-339.0K-563.0K-175.0K-199.0K-55.0K-917.0K-96.0K-449.0K
Free cash flow-171.2M13.0M-59.4M-40.3M-17.6M-32.1M-19.0M-17.3M
Cash from investing56.8M-106.1M-87.2M-199.0K-55.0K-917.0K-96.0K-449.0K
Cash from financing104.6M72.4M6.90M190.7M53.2M408.5M8.61M19.4M
Share buybacks570.0K
Change in cash-9.50M-20.2M-139.5M150.5M35.5M14.2M-10.2M2.08M

Open Financials

Filings

FilingDateTypeFiled with
144 · Notice of proposed saleNov 9, 2026Other filingsSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 4, 2026Insider tradeSEC
144 · Notice of proposed saleOct 30, 2026Other filingsSEC
144 · Notice of proposed saleOct 19, 2026Other filingsSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
144 · Notice of proposed saleOct 1, 2026Other filingsSEC
144 · Notice of proposed saleSep 30, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
144 · Notice of proposed saleSep 4, 2026Other filingsSEC
144 · Notice of proposed saleSep 3, 2026Other filingsSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
144 · Notice of proposed saleSep 2, 2026Other filingsSEC
144 · Notice of proposed saleSep 1, 2026Other filingsSEC
144 · Notice of proposed saleAug 31, 2026Other filingsSEC
144 · Notice of proposed saleAug 20, 2026Other filingsSEC
144 · Notice of proposed saleAug 20, 2026Other filingsSEC
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
144 · Notice of proposed saleAug 18, 2026Other filingsSEC
144 · Notice of proposed saleAug 18, 2026Other filingsSEC
3 · Initial statement of ownershipAug 17, 2026Insider tradeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 27, 2026Big-stake noticeSEC
8-K · Current reportJul 17, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 14, 2026Big-stake noticeSEC
8-K · Current reportJul 7, 2026Management or board changeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
8-K · Current reportJun 25, 2026Meeting outcomeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
144 · Notice of proposed saleJun 12, 2026Other filingsSEC
144 · Notice of proposed saleJun 12, 2026Other filingsSEC
3 · Initial statement of ownershipJun 1, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
8-K · Current reportMay 15, 2026ResultsSEC
8-K · Current reportMay 13, 2026Management or board changeSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 27, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 31, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMar 24, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansMar 9, 2026Offer documentSEC
10-K · Annual reportMar 9, 2026Annual reportSEC
8-K · Current reportMar 9, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 21, 2026Big-stake noticeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
144 · Notice of proposed saleNov 13, 2025Other filingsSEC
144 · Notice of proposed saleNov 12, 2025Other filingsSEC
144/A · Notice of proposed sale, amendedNov 12, 2025Other filingsSEC
144 · Notice of proposed saleNov 12, 2025Other filingsSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 1, 2025Big-stake noticeSEC
8-K · Current reportSep 29, 2025Material contractSEC
8-K · Current reportAug 27, 2025Current reportSEC
4 · Change in ownershipAug 22, 2025Insider tradeSEC
4 · Change in ownershipAug 22, 2025Insider tradeSEC
4 · Change in ownershipAug 21, 2025Insider tradeSEC
144 · Notice of proposed saleAug 21, 2025Other filingsSEC
144 · Notice of proposed saleAug 21, 2025Other filingsSEC
144 · Notice of proposed saleAug 19, 2025Other filingsSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 13, 2025ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 1, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 22, 2025Big-stake noticeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 2, 2025Big-stake noticeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
144 · Notice of proposed saleJul 1, 2025Other filingsSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
8-K · Current reportJun 26, 2025Meeting outcomeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
144 · Notice of proposed saleJun 18, 2025Other filingsSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
144 · Notice of proposed saleMay 20, 2025Other filingsSEC
144 · Notice of proposed saleMay 20, 2025Other filingsSEC
144 · Notice of proposed saleMay 20, 2025Other filingsSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
8-K · Current reportMay 2, 2025Material contractSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
144 · Notice of proposed saleApr 7, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 24, 2025Big-stake noticeSEC
4 · Change in ownershipMar 21, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMar 20, 2025Offer documentSEC
144 · Notice of proposed saleMar 20, 2025Other filingsSEC
10-K · Annual reportMar 20, 2025Annual reportSEC
8-K · Current reportMar 20, 2025ResultsSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
144 · Notice of proposed saleMar 5, 2025Other filingsSEC
8-K · Current reportMar 5, 2025Current reportSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 3, 2025Other filingsSEC
S-3ASR · Registration statementJan 31, 2025Offer documentSEC
8-K · Current reportJan 13, 2025ResultsSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
144 · Notice of proposed saleJan 6, 2025Other filingsSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2024Insider tradeSEC
4 · Change in ownershipDec 19, 2024Insider tradeSEC
4 · Change in ownershipDec 13, 2024Insider tradeSEC
4 · Change in ownershipDec 13, 2024Insider tradeSEC
144 · Notice of proposed saleDec 13, 2024Other filingsSEC
4 · Change in ownershipDec 12, 2024Insider tradeSEC
144 · Notice of proposed saleDec 12, 2024Other filingsSEC
4 · Change in ownershipDec 11, 2024Insider tradeSEC
4 · Change in ownershipDec 11, 2024Insider tradeSEC
144 · Notice of proposed saleDec 11, 2024Other filingsSEC
144 · Notice of proposed saleDec 10, 2024Other filingsSEC
144 · Notice of proposed saleDec 10, 2024Other filingsSEC
4 · Change in ownershipDec 9, 2024Insider tradeSEC
4 · Change in ownershipDec 9, 2024Insider tradeSEC
144/A · Notice of proposed sale, amendedDec 9, 2024Other filingsSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
144 · Notice of proposed saleDec 6, 2024Other filingsSEC
10-Q/A · Quarterly report, amendedDec 6, 2024Quarterly reportSEC
144 · Notice of proposed saleDec 5, 2024Other filingsSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC
144 · Notice of proposed saleDec 4, 2024Other filingsSEC
144 · Notice of proposed saleDec 4, 2024Other filingsSEC
144 · Notice of proposed saleDec 3, 2024Other filingsSEC
144 · Notice of proposed saleDec 2, 2024Other filingsSEC
144 · Notice of proposed saleDec 2, 2024Other filingsSEC
144 · Notice of proposed saleDec 2, 2024Other filingsSEC
4 · Change in ownershipNov 27, 2024Insider tradeSEC
UPLOAD · Letter from the SECNov 25, 2024Other filingsSEC
4 · Change in ownershipNov 21, 2024Insider tradeSEC
4 · Change in ownershipNov 21, 2024Insider tradeSEC
CORRESP · Letter to the SECNov 18, 2024Other filingsSEC
144 · Notice of proposed saleNov 15, 2024Other filingsSEC
4 · Change in ownershipNov 14, 2024Insider tradeSEC
4 · Change in ownershipNov 14, 2024Insider tradeSEC
4 · Change in ownershipNov 13, 2024Insider tradeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
8-K · Current reportNov 12, 2024Material contractSEC
UPLOAD · Letter from the SECNov 7, 2024Other filingsSEC
4 · Change in ownershipOct 17, 2024Insider tradeSEC
4 · Change in ownershipOct 17, 2024Insider tradeSEC
4 · Change in ownershipOct 17, 2024Insider tradeSEC
144 · Notice of proposed saleOct 16, 2024Other filingsSEC
144 · Notice of proposed saleOct 15, 2024Other filingsSEC
8-K · Current reportOct 15, 2024Material contractSEC
4 · Change in ownershipOct 10, 2024Insider tradeSEC
4 · Change in ownershipOct 10, 2024Insider tradeSEC
8-K · Current reportSep 23, 2024Material contractSEC
4 · Change in ownershipSep 19, 2024Insider tradeSEC
4 · Change in ownershipSep 19, 2024Insider tradeSEC
4 · Change in ownershipSep 19, 2024Insider tradeSEC
144 · Notice of proposed saleSep 18, 2024Other filingsSEC
4 · Change in ownershipSep 12, 2024Insider tradeSEC
4 · Change in ownershipSep 12, 2024Insider tradeSEC
144 · Notice of proposed saleSep 10, 2024Other filingsSEC

This page holds 200 of 550 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from ARS Pharmaceuticals, Inc.’s releases · as of Nov 3, 2026

Common shares
100,528,400
Fully diluted
100,528,400

Fully diluted

LineSharesAs of
Common shares100,528,400Nov 3, 2026

Share count over time

CountShares
Nov 3, 2026100,528,400

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Ra Capital Management, L.P.10.9M10.8%US$46.8MNo changeNov 16, 2026
Rubric Capital Management LP8.54M8.5%US$36.8MNo changeNov 16, 2026
Orbimed Advisors LLC8.29M8.2%US$35.7MNo changeNov 16, 2026
Deerfield Management Company, L.P.7.5M7.5%US$32.3MNo changeNov 16, 2026
BlackRock5.58M5.6%US$24.1M+271KNov 13, 2026
UBS4.13M4.1%US$17.8M+1.73MNov 16, 2026
Sr One Capital Management, LP4.01M4.0%US$17.3MNo changeNov 16, 2026
State Street3.69M3.7%US$15.9M−42,043Nov 12, 2026
Vanguard3.6M3.6%US$15.5M−55,194Nov 13, 2026
Millennium3.27M3.3%US$14.1M+869KNov 16, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Tyro Capital Management LLC3.2M3.2%US$13.8M−1.26MNov 12, 2026
Capital Group1.96M2.0%US$8.45M−794KNov 12, 2026
abrdn1.7M1.7%US$7.33M−2.47MNov 10, 2026
Geode Capital1.6M1.6%US$6.89M−99,692Nov 6, 2026
Janney Montgomery Scott LLC1.54M1.5%US$6.65M−522KNov 12, 2026
Creek Drive Management Group LLC1.13M1.1%US$4.85MNewNov 10, 2026
Citadel1.08M1.1%US$4.65M+548KNov 16, 2026
Third Point LLC1M0.99%US$4.31MNo changeNov 16, 2026
General American Investors Co Inc908K0.90%US$3.92M−225KNov 2, 2026
K2 Principal Fund, L.P.662K0.66%US$2.85M+287KNov 13, 2026
Pavaki Capital Management LLC660K0.66%US$2.84M+80,000Oct 26, 2026
Trexquant Investment LP600K0.60%US$2.59M+313KNov 16, 2026
Tejara Capital Ltd589K0.59%US$2.54M−17,997Nov 9, 2026
ADAR1 Capital Management, LLC561K0.56%US$2.42M−40,000Nov 16, 2026
Northern Trust545K0.54%US$2.35M−3,613Nov 16, 2026
Landscape Capital Management, L.L.C.483K0.48%US$2.08MNewNov 10, 2026
Schwab478K0.48%US$2.06M−73,542Nov 16, 2026
Empire Life Investments Inc.469K0.47%US$2.02M−2,697Nov 6, 2026
FIL Ltd456K0.45%US$1.96MNo changeNov 10, 2026
Marshall Wace, LLP450K0.45%US$1.94M+326KNov 13, 2026
Eversept Partners, LP449K0.45%US$1.94M+72,158Nov 16, 2026
CenterBook Partners LP419K0.42%US$1.81M+296KNov 2, 2026
Investment Management Associates Inc393K0.39%US$1.7M+19,937Oct 29, 2026
Morgan Stanley375K0.37%US$1.61M+146KNov 13, 2026
Levin Capital Strategies, L.P.369K0.37%US$1.59M−179KNov 2, 2026
Raymond James Financial Inc365K0.36%US$1.57M+46,714Nov 12, 2026
Goldman Sachs325K0.32%US$1.4M−56,089Nov 16, 2026
Bank of America300K0.30%US$1.29M−163KNov 16, 2026
Hennion & Walsh Asset Management, Inc.252K0.25%US$1.09M+76,863Oct 13, 2026
FAS Wealth Partners, Inc.244K0.24%US$1.05M+29,825Nov 16, 2026
Quantinno Capital Management LP221K0.22%US$953K+96,687Nov 13, 2026
Nuveen203K0.20%US$874K+41,422Nov 10, 2026
Ishara Investments LP200K0.20%US$862K+56,510Nov 16, 2026
DAFNA Capital Management LLC183K0.18%US$788K+18,500Nov 16, 2026
Quinn Opportunity Partners LLC175K0.17%US$754KNo changeNov 10, 2026
Renaissance Technologies174K0.17%US$751KNewNov 12, 2026
BNY170K0.17%US$732K+1,620Nov 5, 2026
Balyasny Asset Management L.P.164K0.16%US$708K+99,583Nov 16, 2026
State Of Wisconsin Investment Board127K0.13%US$546K+113KNov 16, 2026
Barclays125K0.12%US$540K−923Nov 6, 2026

This page holds 50 of 184 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
SMALLCAP World Fund Inc2.68M2.7%US$21.5MNewJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2.29M2.3%US$18.3M+73,535Jun 30, 2026
Vanguard Total Stock Market Index Fund1.75M1.7%US$14MNo changeJun 30, 2026
iShares Russell 2000 ETF1.61M1.6%US$12.9M+159KJun 30, 2026
Vanguard Extended Market Index Fund746K0.74%US$5.98M+11,746Jun 30, 2026
Fidelity Small Cap Index Fund670K0.67%US$3.44M+86,634Jul 31, 2026
iShares Russell 2000 Growth ETF578K0.58%US$4.63M+101KJun 30, 2026
iShares Biotechnology ETF442K0.44%US$3.54M−21,289Jun 30, 2026
Fidelity Extended Market Index Fund339K0.34%US$3.08M−4,411May 31, 2026
Select Biotechnology Portfolio335K0.33%US$3.04MNo changeMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
Schwab U.S. Small-Cap ETF311K0.31%US$2.82M−5,014May 31, 2026
Vanguard Russell 2000 Index Fund304K0.30%US$2.75M+10,996May 31, 2026
Optimum Small-Mid Cap Growth Fund220K0.22%US$1.76MNewJun 30, 2026
Vanguard Health Care Index Fund162K0.16%US$1.47M−1,379May 31, 2026
Schwab Small-Cap Index Fund150K0.15%US$769K+22,959Jul 31, 2026
JPMorgan U.S. Small Company Fund126K0.13%US$1.01M−9,134Jun 30, 2026
Fidelity Total Market Index Fund125K0.12%US$1.13MNo changeMay 31, 2026
Master Small Cap Index Series117K0.12%US$938K+22,519Jun 30, 2026
Empower Small Cap Growth Fund110K0.11%US$877KNewJun 30, 2026
ALPS Medical Breakthroughs ETF102K0.10%US$928K+14,252May 31, 2026
Fidelity Series Total Market Index Fund99,4740.10%US$902K+4,860May 31, 2026
Nuveen Small Cap Blend Index Fund81,8120.08%US$420K+10,646Jul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF81,0430.08%US$649K+1,904Jun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares77,7140.08%US$399K−48,902Jul 31, 2026
Sit Small Cap Growth Fund73,1000.07%US$586KNo changeJun 30, 2026
SMALLCAP World Fund72,7430.07%US$583KNewJun 30, 2026
EQ/2000 Managed Volatility Portfolio66,9990.07%US$537K+3,129Jun 30, 2026
Nuveen Equity Index Fund64,9970.06%US$333KNo changeJul 31, 2026
Fidelity Nasdaq Composite Index Fund59,3770.06%US$539K+2,601May 31, 2026
Fidelity Small Cap Growth Index Fund57,7260.06%US$462K+12,890Jun 30, 2026
Vanguard Russell 2000 Growth Index Fund55,2570.05%US$501K+963May 31, 2026
Royce Smaller-Companies Growth Fund54,0000.05%US$433KNo changeJun 30, 2026
iShares U.S. Small-Cap Equity Factor ETF51,1920.05%US$263K−118KJul 31, 2026
Schwab U.S. Broad Market ETF48,1090.05%US$436K+479May 31, 2026
Schwab Total Stock Market Index Fund41,9000.04%US$215KNo changeJul 31, 2026
LVIP State Street Small-Cap Index Fund40,2000.04%US$322KNo changeJun 30, 2026
Fidelity Nasdaq Composite Index ETF40,1470.04%US$364K−491May 31, 2026
Dimensional U.S. Small Cap ETF39,5690.04%US$203K−43,820Jul 31, 2026
Fidelity ZERO Total Market Index Fund34,8280.03%US$179K+1,931Jul 31, 2026
Small Cap Index Fund31,8570.03%US$255K+5,981Jun 30, 2026
Vanguard Balanced Index Fund30,2130.03%US$242KNo changeJun 30, 2026
Global X Russell 2000 ETF29,4260.03%US$151K+3,800Jul 31, 2026
LVIP JPMorgan Small Cap Core Fund28,2210.03%US$226K−1,595Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund27,7430.03%US$222KNo changeJun 30, 2026
EQ/Small Company Index Portfolio27,2300.03%US$218KNo changeJun 30, 2026
Fidelity ZERO Extended Market Index Fund25,2480.03%US$130K+2,224Jul 31, 2026
Small Cap Index Fund22,4630.02%US$204K−460May 31, 2026
Fidelity MSCI Health Care Index ETF22,3920.02%US$115K−2,525Jul 31, 2026
EQ/AB Small Cap Growth Portfolio22,1200.02%US$177K+17,510Jun 30, 2026
Biotechnology Ultrasector Profund21,8060.02%US$112K−17,379Jul 31, 2026

This page holds 50 of 127 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Fitzpatrick Alexander A
Officer: Chief Legal Officer
Sale3,355USD 10.00US$33,550Jun 12, 2026
Karas Eric
Officer: Chief Commercial Officer
Sale25,000USD 10.00US$250KJun 12, 2026

Big stakes

HolderStakeSharesDate
Ra Capital Management, L.P.11.10%10.9MSep 29, 2025
Rubric Capital Management LP8.06%8MMar 31, 2026
Deerfield Management Company, L.P.7.75%7.61MJul 30, 2025
BlackRock, Inc.5.30%5.22MJun 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Peter Kolchinsky
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Wave Life Sciences Ltd. (Director · Since at least Aug 14, 2015); Black Diamond Therapeutics, Inc. (Director · Jul 5, 2023 – Jul 5, 2023 · Past); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Research Alliance Corp II (Chief Executive Officer, Director · Mar 17, 2021 – Mar 17, 2021 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Solid Biosciences Inc. (Director · Dec 10, 2020 – Jan 11, 2024 · Past); POINT Biopharma Global Inc (Chief Executive Officer, Director · Jul 7, 2020 – Jun 29, 2021 · Past); Forma Therapeutics Holdings Inc (Director · Jun 18, 2020 – Jun 8, 2022 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 3, 2022 · Past); Synthorx Inc (Director · Dec 6, 2018 – Jan 23, 2020 · Past); Kala Bio, Inc. (Director · Oct 3, 2018 – Mar 13, 2020 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – Jun 19, 2018 · Past); KalVista Pharmaceuticals, Inc. (Director · Oct 12, 2017 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Jun 20, 2017 – Apr 2, 2020 · Past); Dicerna Pharmaceuticals Inc (Director · Jan 29, 2014 – Nov 27, 2019 · Past)
Director · Since at least Nov 8, 2022
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Since at least Nov 8, 2022
James Flynn
Other companies: Lite Strategy, Inc. (Non-Executive Director · Since at least Oct 31, 2023); Nuvalent, Inc. (Director · Since at least Jul 28, 2021); Larimar Therapeutics, Inc. (Director · Since at least May 28, 2020); Synlogic Inc (Director · Mar 19, 2024 – Apr 26, 2025 · Past); BiomX Inc. (Director · Mar 15, 2024 – Apr 21, 2025 · Past); RiceBran Technologies (Director · Jan 3, 2024 – Jan 3, 2024 · Past); Oruka Therapeutics, Inc. (Director · Dec 15, 2022 – Jan 30, 2024 · Past); CareMax Inc (Director · Nov 17, 2022 – Nov 17, 2023 · Past); Da32 Life Science Tech Acquisition Corp (Director · Jul 27, 2021 – Jul 28, 2023 · Past); Oncorus Inc (Director · Oct 1, 2020 – Feb 17, 2021 · Past); Acutus Medical Inc. (Director · Aug 5, 2020 – Jan 27, 2025 · Past); Deerfield Healthcare Technology Acquisitions Corp (Director · Jul 16, 2020 – Jul 21, 2020 · Past); Q32 Bio Inc. (Director · Mar 27, 2018 – Jun 6, 2019 · Past); AdaptHealth Corp. (Director · Feb 15, 2018 – Nov 8, 2019 · Past); Alpine Immune Sciences Inc (Director · Sep 12, 2016 – Sep 12, 2016 · Past); AveXis Inc (Director · Sep 3, 2015 – Feb 10, 2016 · Past)
Director · Nov 8, 2022 – Nov 8, 2022 · Past
Peter Thompson
Other companies: Aspen Neuroscience, Inc. (General Partner · Since at least Nov 2, 2026); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Edgewise Therapeutics, Inc. (Chairman and Co-Founder · Since at least Mar 25, 2021); Corvus Pharmaceuticals, Inc. (CO-FOUNDER · Since at least Mar 22, 2016); Janux Therapeutics, Inc. (Director · Jun 10, 2021 – Jun 14, 2022 · Past); Decibel Therapeutics Inc (Director · Feb 11, 2021 – Jun 17, 2022 · Past); PMV Pharmaceuticals, Inc. (Director · Sep 24, 2020 – Jun 2, 2021 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Synthorx Inc (Director · Dec 6, 2018 – Jan 23, 2020 · Past); Principia Biopharma Inc (Director · Sep 13, 2018 – Sep 13, 2018 · Past); Alpine Immune Sciences Inc (Director · Jul 24, 2017 – May 18, 2024 · Past); Adaptimmune Therapeutics PLC (Director · Jan 1, 2016 – Jun 4, 2018 · Past); Sierra Oncology Inc (Director · Jul 15, 2015 – Jul 21, 2015 · Past); Anthera Pharmaceuticals Inc (Director · Feb 1, 2011 – May 8, 2012 · Past); Trubion Pharmaceuticals Inc (President and CEO, Director · Oct 17, 2006 – Aug 27, 2009 · Past)
Director · Since at least Dec 3, 2020
Vickie Capps
Other companies: Orthofix Medical Inc. (Director · Since at least Mar 11, 2025); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Amedisys Inc (Director · Since at least Nov 1, 2019); Synthorx Inc (Director · Dec 6, 2018 – Jan 23, 2020 · Past); NuVasive Inc (Director · Jun 12, 2015 – Sep 1, 2023 · Past); Connecture Inc (Director · Dec 11, 2014 – Apr 25, 2018 · Past); Otonomy Inc (Director · Aug 12, 2014 – Nov 28, 2022 · Past); Senorx Inc (Director · Jun 14, 2007 – Feb 26, 2010 · Past); Djo Inc (Executive VP, CFO · Jun 28, 2006 – Nov 20, 2007 · Past)
Director · Dec 3, 2020 – Jun 10, 2022 · Past
Robert Hershberg
Other companies: Danaher Corporation (Director · Since at least Nov 15, 2026); AtaiBeckley Inc. (Director · Since at least Jun 4, 2026); Hillevax Inc (President and CEO, Director · Since at least Apr 28, 2022); Recursion Pharmaceuticals, Inc. (Board Member · Since at least Apr 15, 2021); Adaptive Biotechnologies Corporation (Board Member · Since at least Jun 26, 2019); Fate Therapeutics, Inc. (Director · May 1, 2020 – Jun 6, 2023 · Past); NanoString Technologies Inc (Director · Mar 2, 2015 – Apr 18, 2022 · Past); Dendreon Corp (Sr. VP & Chief Medical Officer · Dec 31, 2005 – Jan 19, 2006 · Past)
Director · Dec 3, 2020 – Jun 10, 2022 · Past
Brent Saunders
Other companies: Bausch + Lomb Corporation (Chairman of the Board and CEO, Director · Since at least Mar 6, 2023); SkinHealth Systems Inc. (Chairman · Since at least Sep 29, 2020); BridgeBio Pharma, Inc. (Director · Jun 23, 2020 – Jun 22, 2022 · Past); Cisco Systems, Inc. (Director · Mar 13, 2017 – Dec 8, 2022 · Past); Forest Laboratories Inc (CEO & President, Director · Aug 23, 2011 – Jun 30, 2014 · Past); Merck & Company, Inc. (Senior Vice President · May 19, 2006 – Nov 3, 2009 · Past)
Director · Since at least Nov 8, 2022
Jonathan Leff
Other companies: Larimar Therapeutics, Inc. (Director · Since at least May 28, 2020); BiomX Inc. (Director · Mar 15, 2024 – Apr 14, 2025 · Past); Protara Therapeutics, Inc. (Director · Aug 2, 2017 – Jun 8, 2018 · Past); AveXis Inc (Director · Feb 10, 2016 – Feb 10, 2016 · Past); Alpine Immune Sciences Inc (Director · Jun 16, 2015 – Sep 11, 2015 · Past); InterMune Inc (EVP, Research & Development · Feb 27, 2012 – Sep 29, 2014 · Past)
Director · Nov 8, 2022 – Nov 8, 2022 · Past
Jonathan Root
Other companies: Carlsmed, Inc. (Chair of the Nominating and Corporate Governance Committee · Since at least Jul 22, 2025); Omada Health, Inc. (Director · Since at least Jun 5, 2025); Edgewise Therapeutics, Inc. (Director · Since at least Mar 25, 2021); eFFECTOR Therapeutics Inc (Director · Aug 25, 2021 – Dec 2, 2021 · Past); Inari Medical Inc (Director · May 21, 2020 – Feb 19, 2025 · Past); OncoMed Pharmaceuticals Inc (Director · Jul 17, 2013 – Apr 23, 2019 · Past)
Director · Dec 3, 2020 – Jun 10, 2022 · Past
Phillip Schneider
Other companies: Longboard Pharmaceuticals Inc (Director · Mar 11, 2021 – Dec 2, 2024 · Past); Pfenex Inc (Director · Jul 24, 2014 – Oct 1, 2020 · Past); Auspex Pharmaceuticals Inc (Director · Feb 4, 2014 – May 5, 2015 · Past); Arena Pharmaceuticals Inc (Director · Dec 11, 2007 – Jun 13, 2017 · Past)
Director · Since at least Nov 8, 2022
All 38 people
PersonSeat
Alexander Fitzpatrick
Other companies: Evofem Biosciences, Inc. (General Counsel and Secretary · Jan 17, 2018 – Feb 18, 2022 · Past); Verenium Corp (Sr. VP & General Counsel · Nov 8, 2010 – Oct 31, 2013 · Past); Kintera Inc (SVP and General Counsel · May 2, 2007 – Jul 8, 2008 · Past)
Chief Legal Officer · Since at least Dec 1, 2022
Andrew Kenneth William Powell
Other companies: Synthorx Inc (Director · Dec 19, 2018 – Jan 23, 2020 · Past); Lifecore Biomedical, Inc. (Director · Oct 12, 2018 – Jun 4, 2022 · Past); Aclaris Therapeutics, Inc. (Director · May 16, 2018 – Jun 1, 2024 · Past)
Director · Dec 3, 2020 – Jun 10, 2022 · Past
Brian T. Dorsey
Other companies: Apricus Biosciences Inc (SVP, Chief Development Officer · Dec 1, 2014 – Jan 1, 2018 · Past); Pernix Therapeutics Holdings Inc (SVP Research · Apr 19, 2013 – Oct 10, 2014 · Past); Somaxon Pharmaceuticals Inc (SVP, Technical Operations · Nov 9, 2006 – Dec 31, 2012 · Past)
Chief Operating Officer · Since at least Dec 6, 2022
Kathleen Scott
Other companies: Dermata Therapeutics, Inc. (Director · Since at least Aug 12, 2021); NKGen Biotech Inc. (Director · Sep 29, 2023 – Dec 6, 2024 · Past); Histogen Inc (Director · Nov 18, 2019 – Nov 18, 2019 · Past)
Chief Financial Officer · Since at least Nov 8, 2022
Laura Shawver
Other companies: Relay Therapeutics, Inc. (Director · Jul 15, 2020 – Jun 3, 2024 · Past); Nkarta, Inc. (Director · Jul 9, 2020 – Jun 8, 2022 · Past); Synthorx Inc (President and CEO, Director · Dec 6, 2018 – Jan 23, 2020 · Past)
Director · Since at least Dec 3, 2020
Randall Kaye
Other companies: Longboard Pharmaceuticals Inc (Executive Vice President & CMO · Mar 21, 2022 – Dec 2, 2024 · Past); Axsome Therapeutics, Inc. (Chief Medical Officer · Nov 19, 2015 – Dec 23, 2015 · Past); Avanir Pharmaceuticals Inc (Sr. VP, Chief Medical Officer · Jan 16, 2006 – Sep 9, 2011 · Past)
Chief Medical Officer · Since at least Nov 5, 2026
Thilo Schroeder
Other companies: PMV Pharmaceuticals, Inc. (Director · Sep 24, 2020 – Oct 6, 2021 · Past); Revolution Medicines, Inc. (Director · Feb 12, 2020 – Dec 5, 2024 · Past); IDEAYA Biosciences, Inc. (Director · May 22, 2019 – May 22, 2019 · Past)
Director · Dec 3, 2020 – Dec 8, 2020 · Past
Maria Koehler
Other companies: ImageneBio, Inc. (Director · Apr 15, 2021 – Jun 7, 2024 · Past); Repare Therapeutics Inc (EVP, CHIEF MEDICAL OFFICER · Jun 18, 2020 – Mar 12, 2025 · Past)
Director · Mar 12, 2021 – Jun 10, 2022 · Past
Pratik Shah
Other companies: Design Therapeutics, Inc. (Co-Founder, President, CEO and Chairperson · Since at least Mar 25, 2021); Synthorx Inc (Director · Dec 6, 2018 – Jan 23, 2020 · Past)
Director and Chair of the Board · Since at least Nov 8, 2022
Saqib Islam
Other companies: Passage Bio, Inc. (Director · Since at least May 27, 2021); SpringWorks Therapeutics Inc (Chief Executive Officer, Director · Since at least Jan 7, 2021)
Director · Since at least Dec 3, 2020
Michael Kelly
Other companies: Hemab Therapeutics Holdings, Inc. (Vice President, Clinical Development · Since at least Nov 5, 2026)
Director · Since at least Nov 8, 2022
Valerie Odegard
Other companies: Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026)
President and CSO · Dec 3, 2020 – May 2, 2022 · Past
Brenton SaundersDirector · Since at least Nov 5, 2026
Daniel RelovskySenior Vice President, Marketing · Since at least Nov 5, 2026
Donn CasalePresident, Chief Executive Officer and Director · Since at least Jun 1, 2026
Eric KarasChief Commercial Officer · Since at least Nov 8, 2022
Jeffrey C PepeInterim CEO and GC · Sep 2, 2022 – Sep 2, 2022 · Past
John SlebirChief Legal Officer · Since at least Nov 5, 2026
Jonathan PiazzaChief Financial Officer · Dec 3, 2020 – May 2, 2022 · Past
Justin ChakmaChief Business Officer · Since at least Nov 8, 2022
Lynda HarrisVice President, Human Resources · Since at least Nov 5, 2026
Margaret Ekins SmithChief Commercial Officer · Since at least Aug 17, 2026
Meg SmithChief Commercial Officer · Since at least Aug 13, 2026
Naomi HunderChief Medical Officer · Dec 3, 2020 – May 2, 2022 · Past
Rajeev DadooDirector · Since at least Nov 8, 2022
Richard LowenthalDirector · Since at least Nov 8, 2022
Russ HawkinsonSr. Vice President of Finance · Dec 3, 2020 – May 2, 2022 · Past
Sarina TanimotoCHIEF MEDICAL OFFICER · Since at least Nov 8, 2022

Open People

Log in to ask 6ix AI your own questions about ARS Pharmaceuticals, Inc.